ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Mesenchymal stem cells(HucMSCs)

Its studies are mostly in Heart Failure, led by China Resources Pharmaceutical Group.

Furthest: phase 2, since Nov 20, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Group11 open or runningphase 2since Nov 20, 2025Nov 20, 2025Dec 31, 2026phase 2 · NCT07265349

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2025First study: phase 2 study in Coronary Artery Bypass Grafting (CABG)First studyNCT07265349 · 51 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Coronary Artery Bypass Grafting (CABG)NCT07265349

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265349Coronary Artery Bypass Grafting (CABG) · China2RecruitingDec 31, 202651

How it is read

Names in the registry

  • “Mesenchymal stem cells(HucMSCs)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.